Horizon scanning: Phase II study of MEK162 for advanced melanoma harbouring NRAS or Val600 BRAF mutations

Source: Lancet Oncology Area: News An open-label, non-randomised, phase II study has reported positive data for MEK162  targeted therapy in patients with NRAS -mutated melanoma.    A total of 71 patients with NRAS-mutated (n=30) or BRAF-mutated (n=41) advanced melanoma enrolled at cancer centres in Europe and the USA were assigned to the following three arms:   . twice-daily MEK162 45 mg for NRAS-mutated melanoma, . twice-daily MEK162 45 mg for BRAF-mutated melanoma, . twice-daily MEK162 60 mg for BRAF-mutated melanoma.   The primary endpoint was the proportion of patients who had an objective response (ie, a complete response or confirmed partial response).   At median follow-up of 3.3 months, the following data were reported for the 45mg groups only:   . Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed) as did eight (20%) of 41 patients with BRAF-mutated melanoma (two ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news